HRP20110485T1 - Pirolopirazoli kao potentni inhibitori kinaza - Google Patents
Pirolopirazoli kao potentni inhibitori kinaza Download PDFInfo
- Publication number
- HRP20110485T1 HRP20110485T1 HR20110485T HRP20110485T HRP20110485T1 HR P20110485 T1 HRP20110485 T1 HR P20110485T1 HR 20110485 T HR20110485 T HR 20110485T HR P20110485 T HRP20110485 T HR P20110485T HR P20110485 T1 HRP20110485 T1 HR P20110485T1
- Authority
- HR
- Croatia
- Prior art keywords
- alkylene
- compound according
- image
- alkyl
- membered
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 230000003389 potentiating effect Effects 0.000 title 1
- GZTPJDLYPMPRDF-UHFFFAOYSA-N pyrrolo[3,2-c]pyrazole Chemical class N1=NC2=CC=NC2=C1 GZTPJDLYPMPRDF-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 57
- 125000002947 alkylene group Chemical group 0.000 claims abstract 41
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract 23
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims abstract 19
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 19
- 125000005010 perfluoroalkyl group Chemical group 0.000 claims abstract 16
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims abstract 7
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims abstract 7
- 229910003827 NRaRb Inorganic materials 0.000 claims abstract 6
- 125000002993 cycloalkylene group Chemical group 0.000 claims abstract 6
- 125000004663 dialkyl amino group Chemical group 0.000 claims abstract 5
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims abstract 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims abstract 4
- 229910052799 carbon Inorganic materials 0.000 claims abstract 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract 4
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims abstract 3
- 125000004043 oxo group Chemical group O=* 0.000 claims abstract 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims abstract 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 12
- 239000012453 solvate Substances 0.000 claims 12
- 102000001253 Protein Kinase Human genes 0.000 claims 7
- 108060006633 protein kinase Proteins 0.000 claims 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 5
- 150000003254 radicals Chemical class 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 3
- 125000002393 azetidinyl group Chemical group 0.000 claims 3
- 125000004069 aziridinyl group Chemical group 0.000 claims 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 3
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 125000004980 cyclopropylene group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 150000004820 halides Chemical class 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 1
- 101000987297 Homo sapiens Serine/threonine-protein kinase PAK 4 Proteins 0.000 claims 1
- 102100027940 Serine/threonine-protein kinase PAK 4 Human genes 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 230000017105 transposition Effects 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
- 125000006710 (C2-C12) alkenyl group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Enzymes And Modification Thereof (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64290005P | 2005-01-10 | 2005-01-10 | |
| US73377005P | 2005-11-04 | 2005-11-04 | |
| PCT/IB2005/003975 WO2006072831A1 (en) | 2005-01-10 | 2005-12-28 | Pyrrolopyrazoles, potent kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110485T1 true HRP20110485T1 (hr) | 2011-07-31 |
Family
ID=36463340
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110485T HRP20110485T1 (hr) | 2005-01-10 | 2011-06-30 | Pirolopirazoli kao potentni inhibitori kinaza |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US8067591B2 (ko) |
| EP (1) | EP1838718B1 (ko) |
| JP (1) | JP4250195B2 (ko) |
| KR (1) | KR100919343B1 (ko) |
| CN (1) | CN101115760B (ko) |
| AP (1) | AP2007004061A0 (ko) |
| AT (1) | ATE512972T1 (ko) |
| AU (1) | AU2005323797B2 (ko) |
| BR (1) | BRPI0518509A2 (ko) |
| CA (1) | CA2593428C (ko) |
| CU (1) | CU23778B7 (ko) |
| CY (1) | CY1111752T1 (ko) |
| DK (1) | DK1838718T3 (ko) |
| EA (1) | EA011815B1 (ko) |
| ES (1) | ES2365245T3 (ko) |
| GE (1) | GEP20094785B (ko) |
| HK (1) | HK1114380A1 (ko) |
| HR (1) | HRP20110485T1 (ko) |
| IL (1) | IL184275A0 (ko) |
| MA (1) | MA29141B1 (ko) |
| MX (1) | MX2007008385A (ko) |
| NO (1) | NO20073859L (ko) |
| NZ (1) | NZ556273A (ko) |
| PL (1) | PL1838718T3 (ko) |
| PT (1) | PT1838718E (ko) |
| RS (1) | RS51891B (ko) |
| SI (1) | SI1838718T1 (ko) |
| TN (1) | TNSN07254A1 (ko) |
| WO (1) | WO2006072831A1 (ko) |
| ZA (1) | ZA200705628B (ko) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0620354A2 (pt) * | 2005-12-21 | 2011-11-08 | Pfizer Prod Inc | compostos pirrolopirazóis de carbonilamino e composição farmaceutica que os contém |
| UA96618C2 (en) * | 2007-02-07 | 2011-11-25 | Пфайзер Инк. | 3-amino-pyrrolo[3,4-c] pyrazole- 5 (1h, 4h, 6h) carbaldehyde derivatives as pkc inhibitors |
| WO2008096260A1 (en) | 2007-02-07 | 2008-08-14 | Pfizer Inc. | 3-amino-pyrrolo[3,4-c] pyrazole- 5 (1h, 4h, 6h) carbaldehyde derivatives as pkc inhibitors |
| EP2195321B1 (en) | 2007-04-12 | 2016-10-19 | Pfizer Inc. | 3-amido-pyrrolo[3,4-c]pyrazole-5(1h, 4h,6h) carbaldehyde derivatives as inhibitors of protein kinase c |
| AU2008279097B2 (en) * | 2007-07-25 | 2013-05-02 | Bristol-Myers Squibb Company | Triazine kinase inhibitors |
| FR2928150A1 (fr) | 2008-02-29 | 2009-09-04 | Vetoquinol Sa Sa | Nouveaux derives 7-substitues de 3-carboxy-oxadiazino-quinolones, leur preparation et leur application comme anti-bacteriens |
| JPWO2009130900A1 (ja) * | 2008-04-24 | 2011-08-11 | 日本曹達株式会社 | オキシム誘導体、中間体化合物および植物病害防除剤 |
| EP2145891A1 (en) | 2008-07-09 | 2010-01-20 | Vetoquinol S.A. | 9-substituted-5-carboxy-oxadiazino-quinolone derivatives, their preparation and their application as anti-bacterials |
| EP2485727A4 (en) * | 2009-10-06 | 2013-05-01 | Afraxis Inc | PYRROLOPYRAZOLE FOR THE TREATMENT OF CNS DISEASES |
| KR101483215B1 (ko) | 2010-01-29 | 2015-01-16 | 한미약품 주식회사 | 단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체 |
| WO2012065935A1 (en) | 2010-11-17 | 2012-05-24 | F. Hoffmann-La Roche Ag | Methods of treating tumors |
| TWI565709B (zh) | 2011-07-19 | 2017-01-11 | 英菲尼提製藥股份有限公司 | 雜環化合物及其用途 |
| WO2013113778A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
| WO2013113781A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds i |
| EA201400858A1 (ru) | 2012-02-03 | 2015-01-30 | Басф Се | Фунгицидные пиримидиновые соединения |
| WO2013113720A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
| WO2013113716A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
| WO2013113782A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
| WO2013113776A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
| WO2013113719A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds ii |
| CN104220427A (zh) | 2012-02-03 | 2014-12-17 | 巴斯夫欧洲公司 | 杀真菌嘧啶化合物 |
| WO2013113773A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
| WO2013113791A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
| EA201491667A1 (ru) | 2012-03-13 | 2015-03-31 | Басф Се | Фунгицидные соединения пиримидина |
| WO2013135672A1 (en) | 2012-03-13 | 2013-09-19 | Basf Se | Fungicidal pyrimidine compounds |
| JP2015511598A (ja) | 2012-03-16 | 2015-04-20 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Ｐａｋ１阻害剤を用いて黒色腫を治療する方法 |
| AU2013318283A1 (en) | 2012-09-19 | 2015-03-05 | Novartis Ag | Dihydropyrrolidino-pyrimidines as kinase inhibitors |
| RU2619928C2 (ru) * | 2012-10-15 | 2017-05-22 | Пфайзер Айеленд Фармацойтикалз | Способ получения вориконазола и его аналогов |
| WO2015036059A1 (en) | 2013-09-16 | 2015-03-19 | Basf Se | Fungicidal pyrimidine compounds |
| CN105722833A (zh) | 2013-09-16 | 2016-06-29 | 巴斯夫欧洲公司 | 杀真菌的嘧啶化合物 |
| JP6787314B2 (ja) | 2015-06-15 | 2020-11-18 | 宇部興産株式会社 | 置換ジヒドロピロロピラゾール誘導体 |
| CN104926735A (zh) * | 2015-06-16 | 2015-09-23 | 上海合全药物研发有限公司 | 4-氯-5-氟-2-甲基嘧啶的工业化制备方法 |
| BR112018012914B1 (pt) | 2015-12-22 | 2023-04-18 | SHY Therapeutics LLC | Composto, uso de um composto e composição farmacêutica |
| WO2017144546A1 (en) | 2016-02-23 | 2017-08-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of nasopharyngeal carcinoma |
| JP7258748B2 (ja) | 2016-11-22 | 2023-04-17 | ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド | サイクリン依存性キナーゼ１２（ｃｄｋ１２）の阻害剤およびその使用 |
| KR20200041294A (ko) | 2017-06-21 | 2020-04-21 | 샤이 테라퓨틱스 엘엘씨 | 암, 염증성 질환, 신경발달질환 및 섬유증 질환의 치료를 위하여 Ras 수퍼패밀리와 상호작용하는 화합물 |
| CA3097543A1 (en) * | 2018-04-16 | 2019-10-24 | The Regents Of The University Of California | Pak4 inhibitors and methods of use |
| US20220220480A1 (en) | 2019-04-17 | 2022-07-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treatment of nlrp3 inflammasome mediated il-1beta dependent disorders |
| WO2021198511A1 (en) | 2020-04-03 | 2021-10-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treatment of sars-cov-2 infection |
| CN111454278B (zh) * | 2020-05-15 | 2021-03-19 | 四川大学 | Pak1抑制剂及其合成和在制备抗肿瘤药物中的应用 |
| WO2022008597A1 (en) | 2020-07-08 | 2022-01-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for the treatment of infectious diseases |
| WO2022143911A1 (zh) * | 2020-12-31 | 2022-07-07 | 赛诺哈勃药业（成都）有限公司 | 一种纤溶酶抑制剂、其制备方法及应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3423414A (en) | 1966-01-13 | 1969-01-21 | Ciba Geigy Corp | Pyrazolopyridines |
| US3526633A (en) | 1968-03-06 | 1970-09-01 | American Cyanamid Co | Substituted 2,4,5,6-tetrahydropyrrolo(3,4-c)pyrazoles |
| US3947467A (en) | 1973-08-02 | 1976-03-30 | Eli Lilly And Company | 3-(5-Nitro-2-imidazolyl) pyrazoles |
| JPS5163193A (ja) | 1974-11-26 | 1976-06-01 | Yoshitomi Pharmaceutical | Tetorahidoropirazoropirijinkagobutsuno seizoho |
| US6013500A (en) | 1998-05-21 | 2000-01-11 | The Trustees Of Columbia University In The City Of New York | PAK4, a novel gene encoding a serine/threonine kinase |
| ATE480539T1 (de) | 2000-08-10 | 2010-09-15 | Pfizer Italia Srl | Bizyklische pyrazole wirksam als kinase inhibitoren, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen |
| CA2493637A1 (en) * | 2002-07-25 | 2004-02-12 | Manuela Villa | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| UA81790C2 (uk) * | 2002-12-19 | 2008-02-11 | Фармация Италия С.П.А. | Заміщені піролопіразольні похідні як інгібітори кінази |
| US7141568B2 (en) | 2003-07-09 | 2006-11-28 | Pfizer Italia S.R.L. | Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
-
2005
- 2005-12-28 GE GEAP200510173A patent/GEP20094785B/en unknown
- 2005-12-28 PL PL05850734T patent/PL1838718T3/pl unknown
- 2005-12-28 CN CN2005800480012A patent/CN101115760B/zh not_active Expired - Fee Related
- 2005-12-28 AT AT05850734T patent/ATE512972T1/de active
- 2005-12-28 KR KR1020077018110A patent/KR100919343B1/ko not_active IP Right Cessation
- 2005-12-28 PT PT05850734T patent/PT1838718E/pt unknown
- 2005-12-28 BR BRPI0518509-2A patent/BRPI0518509A2/pt not_active Application Discontinuation
- 2005-12-28 EA EA200701257A patent/EA011815B1/ru not_active IP Right Cessation
- 2005-12-28 WO PCT/IB2005/003975 patent/WO2006072831A1/en active Application Filing
- 2005-12-28 NZ NZ556273A patent/NZ556273A/en not_active IP Right Cessation
- 2005-12-28 EP EP05850734A patent/EP1838718B1/en active Active
- 2005-12-28 US US11/813,658 patent/US8067591B2/en not_active Expired - Fee Related
- 2005-12-28 RS RS20110352A patent/RS51891B/en unknown
- 2005-12-28 DK DK05850734.4T patent/DK1838718T3/da active
- 2005-12-28 AP AP2007004061A patent/AP2007004061A0/xx unknown
- 2005-12-28 SI SI200531320T patent/SI1838718T1/sl unknown
- 2005-12-28 AU AU2005323797A patent/AU2005323797B2/en not_active Ceased
- 2005-12-28 MX MX2007008385A patent/MX2007008385A/es active IP Right Grant
- 2005-12-28 ES ES05850734T patent/ES2365245T3/es active Active
- 2005-12-28 CA CA2593428A patent/CA2593428C/en not_active Expired - Fee Related
- 2005-12-28 JP JP2007549962A patent/JP4250195B2/ja not_active Expired - Fee Related
-
2007
- 2007-06-28 IL IL184275A patent/IL184275A0/en unknown
- 2007-07-04 TN TNP2007000254A patent/TNSN07254A1/en unknown
- 2007-07-09 ZA ZA200705628A patent/ZA200705628B/xx unknown
- 2007-07-09 CU CU20070160A patent/CU23778B7/es not_active IP Right Cessation
- 2007-07-10 MA MA30059A patent/MA29141B1/fr unknown
- 2007-07-23 NO NO20073859A patent/NO20073859L/no not_active Application Discontinuation
-
2008
- 2008-03-19 HK HK08103173.5A patent/HK1114380A1/xx not_active IP Right Cessation
-
2011
- 2011-06-30 HR HR20110485T patent/HRP20110485T1/hr unknown
- 2011-07-20 CY CY20111100716T patent/CY1111752T1/el unknown
- 2011-10-06 US US13/267,302 patent/US8530652B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110485T1 (hr) | Pirolopirazoli kao potentni inhibitori kinaza | |
| IL268030B2 (en) | Bicyclics as allosteric shp2 inhibitors | |
| HRP20161498T1 (hr) | Inhibitori kinaza i njihova upotreba u liječenju raka | |
| CO2022011429A2 (es) | Derivados de arilamida con actividad antitumoral | |
| PT1613315E (pt) | Derivados da quinolina-2-ona para o tratamento de doenças das vias aéreas respiratórias | |
| WO2006084030B1 (en) | Small-molecule hsp90 inhibitors | |
| RS20080002A (en) | N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof | |
| JP2008533191A5 (ko) | ||
| JP7304128B2 (ja) | 白金耐性の克服における使用のためのテキサフィリン－白金（ｉｖ）コンジュゲート及び組成物 | |
| RU2000127751A (ru) | Противоопухолевое средство | |
| JP2020536863A5 (ko) | ||
| HK1051850A1 (en) | Triphenylalkene derivatives and their use as selective estrogen receptor modulators | |
| JP2008508287A5 (ko) | ||
| WO2006040569A8 (en) | Thiophene amide compounds for use in the treatment or prophylaxis of cancers | |
| JP2020506895A5 (ko) | ||
| CA2406080A1 (en) | Antitumoral ecteinascidin derivatives | |
| AU2005286833B2 (en) | Sulfonyl hydrazines as hypoxia-selective antineoplastic agents | |
| JP2015522551A5 (ko) | ||
| EP3154689A1 (en) | Complexes | |
| RU2003113538A (ru) | Модифицированные пролекарственные формы ap/amp | |
| JP2016514160A5 (ko) | ||
| RU2008143556A (ru) | Производные тиазолилдигидроиндазола в качестве ингибиторов протеинкиназ | |
| JP2008540438A5 (ko) | ||
| MX2021000462A (es) | Derivados de pirrolo-[1,2-b]-piridazina. | |
| JP2005511762A5 (ko) |